Expression patterns and the prognostic value of the SMYD family members in human breast carcinoma using integrative bioinformatics analysis

Song,Jianping; Liu,Yanfeng; Chen,Qian; Yang,Jinhuan; Jiang,Zhengchen; Zhang,Hao; Liu,Zhaojian; Jin,Bin

doi:10.3892/ol.2019.10054

Expression patterns and the prognostic value of the SMYD family members in human breast carcinoma using integrative bioinformatics analysis

Authors:
- Jianping Song
- Yanfeng Liu
- Qian Chen
- Jinhuan Yang
- Zhengchen Jiang
- Hao Zhang
- Zhaojian Liu
- Bin Jin
View Affiliations

Affiliations: Department of General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250112, P.R. China, Department of Oncology, Qilu Hospital of Shandong University, Jinan, Shandong 250112, P.R. China, Institute of Cell Biology, Shandong University School of Basic Medicine, Jinan, Shandong 250012, P.R. China
Published online on: February 19, 2019 https://doi.org/10.3892/ol.2019.10054
Pages: 3851-3861
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Suppressor of variegation, Enhancer of Zeste, Trithorax and Myeloid‑Nervy‑DEAF1 domain‑containing (SMYD) proteins are a set of lysine methyltransferases involved in a range of diverse biological functions, including gene expression, and regulation of skeletal and cardiac‑muscle development. These proteins may additionally serve roles in a number of different types of cancer. However, the roles of the five SMYD proteins, SMYD 1/2/3/4/5, their expression patterns and prognostic value remain unclear. In the present study, the transcriptional expression levels of the five SMYD proteins were compared with the survival data of patients with breast carcinoma (BC) from the ONCOMINE dataset, Breast Cancer Gene‑Expression Miner v4.0, Kaplan‑Meier Plotter, The Cancer Genome Atlas and cBioPortal. An increase in the SMYD2/3/5 mRNA expression levels and a decrease in SMYD1/4 mRNA expression levels in BC tissues compared with normal tissues were identified. Increased SMYD3 mRNA and decreased SMYD5 mRNA expression levels were associated with decreased levels of histological differentiation, according to the Scarff‑Bloom‑Richardson grading system. Kaplan‑Meier curves demonstrated that the increased SMYD1/4 and decreased SMYD2/3 mRNA expression levels were associated with good relapse‑free survival (RFS) in patients with BC. Furthermore, SMYD2 mRNA expression levels were associated with the RFS of patients with BC with metastatic relapse, and SMYD4 may serve as a tumor suppressor in patients with BC, as patients with increased SMYD4 mRNA expression levels had significantly better RFS compared with decreased SMYD4 mRNA expression levels. The present data suggested that SMYD2 and SMYD3 may be potential biomarkers for diagnosis of BC. Additionally, SMYD2 and SMYD4 may be potential prognostic indicators of patients with BC.

View Figures

View References

1	DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011. View Article : Google Scholar : PubMed/NCBI
2	Fan L, Strasser-Weippl K, Li JJ, St LJ, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
4	Onitilo AA, Engel JM, Greenlee RT and Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clin Med Res. 7:4–13. 2009. View Article : Google Scholar : PubMed/NCBI
5	Du SJ, Tan X and Zhang J: SMYD proteins: Key regulators in skeletal and cardiac muscle development and function. Anat Rec (Hoboken). 297:1650–1662. 2014. View Article : Google Scholar : PubMed/NCBI
6	Doughan M, Spellmon N, Li C and Yang Z: SMYD proteins in immunity: Dawning of a new era. AIMS Biophys. 3:450–455. 2016. View Article : Google Scholar : PubMed/NCBI
7	Leinhart K and Brown M: SET/MYND lysine methyltransferases regulate gene transcription and protein activity. Genes (Basel). 2:210–218. 2011. View Article : Google Scholar : PubMed/NCBI
8	Spellmon N, Holcomb J, Trescott L, Sirinupong N and Yang Z: Structure and function of SET and MYND domain-containing proteins. Int J Mol Sci. 16:1406–1428. 2015. View Article : Google Scholar : PubMed/NCBI
9	Sakamoto LH, Andrade RV, Felipe MS, Motoyama AB and Pittella SF: SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor. Leuk Res. 38:496–502. 2014. View Article : Google Scholar : PubMed/NCBI
10	Hu L, Zhu YT, Qi C and Zhu YJ: Identification of Smyd4 as a potential tumor suppressor gene involved in breast cancer development. Cancer Res. 69:4067–4072. 2009. View Article : Google Scholar : PubMed/NCBI
11	Sealfon SC and Chu TT: RNA and DNA microarrays. Methods Mol Biol. 671:3–34. 2011. View Article : Google Scholar : PubMed/NCBI
12	Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
13	Jézéquel P, Campone M, Gouraud W, Guérin-Charbonnel C, Leux C, Ricolleau G and Campion L: bc-GenExMiner: An easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat. 131:765–775. 2012. View Article : Google Scholar : PubMed/NCBI
14	Jézéquel P, Frénel JS, Campion L, Guérin-Charbonnel C, Gouraud W, Ricolleau G and Campone M: bc-GenExMiner 3.0: New mining module computes breast cancer gene expression correlation analyses. Database (Oxford). 2013:bas0602013. View Article : Google Scholar : PubMed/NCBI
15	Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
16	Li Q, Birkbak NJ, Gyorffy B, Szallasi Z and Eklund AC: Jetset: Selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics. 12:4742011. View Article : Google Scholar : PubMed/NCBI
17	Cancer Genome Atlas Network, . Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
18	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:2013. View Article : Google Scholar
19	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
20	Martinazzi M, Zampatti C, Crivelli F, Zampieri A and Martinazzi S: Scarff-bloom-richardson histoprognostic grading correlates with the immunohistochemical expressions of genomic alterations in infiltrating ductal carcinomas (nos) of the breast. Oncol Rep. 1:1087–1091. 1994.PubMed/NCBI
21	Nicolai P, Redaelli de Zinis LO, Tomenzoli D, Barezzani MG, Bertoni F, Bignardi M and Antonelli AR: Prognostic determinants in supraglottic carcinoma: Univariate and Cox regression analysis. Head Neck. 19:323–34. 1997. View Article : Google Scholar : PubMed/NCBI
22	Hsu CL and Lee WC: Detecting differentially expressed genes in heterogeneous diseases using half student's t-test. Int J Epidemiol. 39:1597–1604. 2010. View Article : Google Scholar : PubMed/NCBI
23	Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 486:346–352. 2012. View Article : Google Scholar : PubMed/NCBI
24	Gottlieb PD, Pierce SA, Sims RJ, Yamagishi H, Weihe EK, Harriss JV, Maika SD, Kuziel WA, King HL, Olson EN, et al: Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. Nat Genet. 31:25–32. 2002. View Article : Google Scholar : PubMed/NCBI
25	Everett AD: Identification, cloning, and developmental expression of hepatoma-derived growth factor in the developing rat heart. Dev Dyn. 222:450–458. 2001. View Article : Google Scholar : PubMed/NCBI
26	Al-Shar'i NA and Alnabulsi SM: Explaining the autoinhibition of the SMYD enzyme family: A theoretical study. J Mol Graph Model. 68:147–157. 2016. View Article : Google Scholar : PubMed/NCBI
27	Yang J and Everett AD: Hepatoma-derived growth factor represses SET and MYND domain containing 1 gene expression through interaction with C-terminal binding protein. J Mol Biol. 386:938–950. 2009. View Article : Google Scholar : PubMed/NCBI
28	Hu TH, Huang CC, Liu LF, Lin PR, Liu SY, Chang HW, Changchien CS, Lee CM, Chuang JH and Tai MH: Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer. 98:1444–1456. 2003. View Article : Google Scholar : PubMed/NCBI
29	Chen SC, Kung ML, Hu TH, Chen HY, Wu JC, Kuo HM, Tsai HE, Lin YW, Wen ZH, Liu JK, et al: Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial-mesenchymal transition. J Pathol. 228:158–169. 2012. View Article : Google Scholar : PubMed/NCBI
30	Li LX, Zhou JX, Calvet JP, Godwin AK, Jensen RA and Li X: Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression. Cell Death Dis. 9:3262018. View Article : Google Scholar : PubMed/NCBI
31	Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T and Berger SL: Repression of p53 activity by Smyd2-mediated methylation. Nature. 444:629–632. 2006. View Article : Google Scholar : PubMed/NCBI
32	Nakakido M, Deng Z, Suzuki T, Dohmae N, Nakamura Y and Hamamoto R: Dysregulation of AKT pathway by SMYD2-mediated lysine methylation on PTEN. Neoplasia. 17:367–373. 2015. View Article : Google Scholar : PubMed/NCBI
33	Wang T, Wu H, Liu S, Lei Z, Qin Z, Wen L, Liu K, Wang X, Guo Y, Liu Q, et al: SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance. Cancer Lett. 430:11–24. 2018. View Article : Google Scholar : PubMed/NCBI
34	Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, et al: SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 510:283–287. 2014. View Article : Google Scholar : PubMed/NCBI
35	Kim JM, Kim K, Schmidt T, Punj V, Tucker H, Rice JC, Ulmer TS and An W: Cooperation between SMYD3 and PC4 drives a distinct transcriptional program in cancer cells. Nucleic Acids Res. 43:8868–8883. 2015. View Article : Google Scholar : PubMed/NCBI
36	Tsai CH, Chen YJ, Yu CJ, Tzeng SR, Wu IC, Kuo WH, Lin MC, Chan NL, Wu KJ and Teng SC: SMYD3-Mediated H2A.Z.1 Methylation promotes cell cycle and cancer proliferation. Cancer Res. 76:6043–6053. 2016. View Article : Google Scholar : PubMed/NCBI
37	Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y and Furukawa Y: Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 97:113–118. 2006. View Article : Google Scholar : PubMed/NCBI
38	Frank B, Hemminki K, Wappenschmidt B, Klaes R, Meindl A, Schmutzler RK, Bugert P, Untch M, Bartram CR and Burwinkel B: Variable number of tandem repeats polymorphism in the SMYD3 promoter region and the risk of familial breast cancer. Int J Cancer. 118:2917–2918. 2006. View Article : Google Scholar : PubMed/NCBI
39	Kidder BL, He R, Wangsa D, Padilla-Nash HM, Bernardo MM, Sheng S, Ried T and Zhao K: SMYD5 Controls heterochromatin and chromosome integrity during embryonic stem cell differentiation. Cancer Res. 77:6729–6745. 2017. View Article : Google Scholar : PubMed/NCBI
40	Kidder BL, Hu G, Cui K and Zhao K: SMYD5 regulates H4K20me3-marked heterochromatin to safeguard ES cell self-renewal and prevent spurious differentiation. Epigenetics Chromatin. 10:82017. View Article : Google Scholar : PubMed/NCBI